-Reuters
Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease
Forma Therapeutics Holdings Inc (NASDAQ:FMTX) announced new data from its ongoing Phase 1 trial of etavopivat (FT-4202) in sickle cell disease.…